Conferences IAS 2009
Other Infections
IAS 2009: Tenofovir/emtricitabine (Truvada) plus Lopinavir/ritonavir (Kaletra) or Raltegravir (Isentress) Work Well for Post-exposure Prophylaxis
- Details
- Category: HIV Prevention
- Published on Friday, 11 September 2009 13:49
- Written by Liz Highleyman
Post-exposure prophylaxis (PEP) regimens consisting of tenofovir/emtricitabine (Truvada) plus lopinavir/ritonavir (Kaletra) or raltegravir (Isentress) prevent HIV infection as well as zidovudine/lamivudine (Combivir) regimens, but with fewer side effects, according to 2 presentations at the recent 5th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention (IAS 2009) in Cape Town, South Africa.
IAS 2009: Vitamin D Deficiency is Common among HIV Positive People and Is Associated with NNRTI Use, Black Race, and Smoking
- Details
- Category: HIV-Related Conditions
- Published on Tuesday, 01 September 2009 13:49
- Written by Liz Highleyman
Two research teams presented study findings at the recent 5th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention (IAS 2009) in Cape Town, South Africa, showing that inadequate vitamin D levels are highly prevalent among people with HIV, and individuals taking efavirenz (Sustiva) are at particularly high risk
IAS 2009: HIV/HCV Coinfected Patients Treated with NRTI-Sparing Antiretroviral Regimens Respond Better to Pegylated Interferon plus Ribavirin
- Details
- Category: HIV/HCV Coinfection
- Published on Tuesday, 11 August 2009 13:49
- Written by Liz Highleyman
HIV/HCV coinfected patients treated with pegylated interferon plus ribavirin achieved a sustained virological (SVR) rate of 54% -- the same as HIV negative individuals -- and sustained response was more likely in patients who did not take a nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) as part of their combination antiretroviral regimen.
IAS 2009: Lipid and Glucose Changes Related to Boosted Darunavir (Prezista) in Children and Adolescents with HIV: DELPHI Study
- Details
- Category: Children & Adolescents
- Published on Tuesday, 18 August 2009 13:49
- Written by Liz Highleyman
Ritonavir-boosted darunavir (Prezista) was effective and generally well-tolerated at week 48 among treatment-experienced children and adolescents with HIV in the DELPHI study, according to a presentation at the 5th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention (IAS 2009) last month in Cape Town, South Africa. No change was seen in glucose levels after starting the drug, and triglyceride levels decreased significantly.
IAS 2009: Can People in Low-income Countries Benefit from Antiretroviral Therapy without Routine Laboratory Monitoring?
- Details
- Category: HIV Treatment
- Published on Friday, 31 July 2009 13:49
- Written by HIVandHepatitis.com
Antiretroviral therapy (ART) should not be withheld from HIV patients in medium- and low-income countries due to lack of laboratory monitoring, according to results of the Development of Antiretroviral Therapy (DART) in Africa trial, presented last week at the 5th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention (IAS 2009) in Cape Town, South Africa. The researchers also concluded that first-line treatment regimens can be given to people in resource-limited countries without the need for routine laboratory monitoring of toxicity.
IAS 2009: ARIES Trial Shows Unboosted Atazanavir (Reyataz) Maintains Viral Suppression as well as Boosted Drug
- Details
- Category: HIV Treatment
- Published on Friday, 14 August 2009 13:49
- Written by Liz Highleyman
The protease inhibitor atazanavir (Reyataz), taken with abacavir/lamivudine (Epzicom coformulation), was as likely to keep viral load undetectable after initial suppression as the same combination plus a boosting dose of ritonavir, researchers reported at the 5th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention (IAS 2009) last month in Cape Town, South Africa. The unboosted regimen, however, was less likely to cause cholesterol and triglyceride elevations.
IAS 2009: At Opening of International AIDS Conference in South Africa, Scientists Warn against Cutting Back Funding for AIDS Programs
- Details
- Category: HIV Treatment
- Published on Tuesday, 21 July 2009 13:49
- Written by IAS
As more than 5,000 researchers, people with HIV/AIS and HIV community advocates gathered in Cape Town, South Africa for the 5th IAS Conference on HIV Pathogenesis, Treatment an AIDS (IAS 2009), July 19 - 22, 2009, speakers at the open ceremonies warned against a loss of momentum in the global fight against the HIV pandemic. There is heightened concern that due to the global recession, governments and other donors are scaling back on their financial support for healthcare delivery systems.
Web Design and Development by